Your session is about to expire
← Back to Search
siRNA
RXI-109 for Age-Related Macular Degeneration
Phase 1 & 2
Waitlist Available
Research Sponsored by RXi Pharmaceuticals, Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up seven (7) months
Awards & highlights
Summary
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109 administered by intravitreal injection to reduce the progression of subretinal fibrosis in subjects with advanced neovascular age-related macular degeneration (NVAMD).
Eligible Conditions
- Age-Related Macular Degeneration
- Subretinal Scarring
- Subretinal Fibrosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ seven (7) months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~seven (7) months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence, severity and relationship of AEs, including clinically significant changes in physical examination findings, ocular examinations and assessments, and clinical laboratory results
Pharmacokinetic profile of RXI-109 in blood
Secondary study objectives
Changes from baseline in BCVA using the Early Treatment Diabetic Retinopathy (ETDRS) chart
Relative change (%) of subretinal fibrosis lesion size compared to baseline using standard ophthalmologic imaging.
Other study objectives
Relative change (%) of CTGF protein levels in aqueous fluid compared to baseline
Trial Design
1Treatment groups
Experimental Treatment
Group I: RXI-109Experimental Treatment1 Intervention
Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RXI-109
2012
Completed Phase 2
~80
Find a Location
Who is running the clinical trial?
RXi Pharmaceuticals, Corp.Lead Sponsor
6 Previous Clinical Trials
194 Total Patients Enrolled
Gerrit DispersynStudy DirectorRXi Pharmaceuticals
Share this study with friends
Copy Link
Messenger